Search research articles
Contact Us
Filters
Showing results (91-100 of 121) with videos related to
Page
of 13
Sort By:
British Journal of Clinical Pharmacology
|
August 21, 2023
Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV-1-infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS-MIE-BIRIDER study)
Florian Lemaitre, Jennifer Lagoutte-Renosi, Marie-Claude Gagnieu, et al.
Antiviral Therapy
|
September 2, 2016
ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study)
Farid Kheloufi, Isabelle Poizot-Martin, Rodolphe Garraffo, et al.
HIV Clinical Trials
|
April 15, 2016
Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study
Isabelle Poizot-Martin, Eric Bellissant, Rodolphe Garraffo, et al.
The Journal of Antimicrobial Chemotherapy
|
January 23, 2023
Comment on: Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV
Sihem Benaboud, Caroline Solas, Stephane Bouchet, et al.
British Journal of Clinical Pharmacology
|
May 14, 2011
Lopinavir/ritonavir population pharmacokinetics in neonates and infants
Saik Urien, Ghislaine Firtion, Suzanne T Anderson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 19, 2019
Recurrence and Occurrence of Kaposi's Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia
Romain Palich, Marianne Veyri, Marc-Antoine Valantin, et al.
Nature Communications
|
March 20, 2021
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
Jean-Sélim Driouich, Maxime Cochin, Guillaume Lingas, et al.
Antiviral Research
|
March 6, 2020
Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates
Vincent Madelain, Aurélie Duthey, France Mentré, et al.
Clinical Pharmacology and Therapeutics
|
February 6, 2021
Neglecting Plasma Protein Binding in COVID-19 Patients Leads to a Wrong Interpretation of Lopinavir Overexposure
Francoise Stanke-Labesque, Didier Concordet, Zoubir Djerada, et al.
The Journal of Antimicrobial Chemotherapy
|
July 3, 2026
Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing
Paul-Rémi Petit, Franck Touret, Jean-Sélim Driouich, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 121) with videos related to
Sort By:
Page
of 13
British Journal of Clinical Pharmacology
|
August 21, 2023
Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV-1-infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS-MIE-BIRIDER study)
Florian Lemaitre, Jennifer Lagoutte-Renosi, Marie-Claude Gagnieu, et al.
Antiviral Therapy
|
September 2, 2016
ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study)
Farid Kheloufi, Isabelle Poizot-Martin, Rodolphe Garraffo, et al.
HIV Clinical Trials
|
April 15, 2016
Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study
Isabelle Poizot-Martin, Eric Bellissant, Rodolphe Garraffo, et al.
The Journal of Antimicrobial Chemotherapy
|
January 23, 2023
Comment on: Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV
Sihem Benaboud, Caroline Solas, Stephane Bouchet, et al.
British Journal of Clinical Pharmacology
|
May 14, 2011
Lopinavir/ritonavir population pharmacokinetics in neonates and infants
Saik Urien, Ghislaine Firtion, Suzanne T Anderson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 19, 2019
Recurrence and Occurrence of Kaposi's Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia
Romain Palich, Marianne Veyri, Marc-Antoine Valantin, et al.
Nature Communications
|
March 20, 2021
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
Jean-Sélim Driouich, Maxime Cochin, Guillaume Lingas, et al.
Antiviral Research
|
March 6, 2020
Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates
Vincent Madelain, Aurélie Duthey, France Mentré, et al.
Clinical Pharmacology and Therapeutics
|
February 6, 2021
Neglecting Plasma Protein Binding in COVID-19 Patients Leads to a Wrong Interpretation of Lopinavir Overexposure
Francoise Stanke-Labesque, Didier Concordet, Zoubir Djerada, et al.
The Journal of Antimicrobial Chemotherapy
|
July 3, 2026
Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing
Paul-Rémi Petit, Franck Touret, Jean-Sélim Driouich, et al.
Page
of 13